586 Phase II study of Telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma

• Manish Shah,
• David Carr-Locke,
• Sandipto Sarkar,
• Sahrish Khan,
• Jennifer Rachel Eads,
• Reem Sharaiha,
• Lillian Chang,
• Gregory Ginsberg,
• Lisa DiCicco,
• Luis Garcia-Marcano,
• Erika Hissong,
• Doron Betel

Affiliations

Manish Shah

2BerbeeWalsh Department of Emergency Medicine, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA

David Carr-Locke

1Weill Cornell Medicine, New York, NY, USA

Sandipto Sarkar

1Weill Cornell Medicine, New York, NY, USA

Sahrish Khan

1Weill Cornell Medicine, New York, NY, USA

Jennifer Rachel Eads

2University of Pennsylvania, Philadelphia, PA, USA

Reem Sharaiha

1Weill Cornell Medicine, New York, NY, USA

Lillian Chang

1Weill Cornell Medicine, New York, NY, USA

Gregory Ginsberg

2University of Pennsylvania, Philadelphia, PA, USA

Lisa DiCicco

2University of Pennsylvania, Philadelphia, PA, USA

Luis Garcia-Marcano

Erika Hissong

3New York-Presbyterian Hospital, New York, NY, USA

Doron Betel

2University of Pennsylvania, Philadelphia, PA, USA